FEATURES OF RESIDUAL PHENOMENA AND CONSEQUENCES OF COVID-19 (REVIEW)

Vestnik ◽  
2021 ◽  
pp. 335-340
Author(s):  
Г.Н. Абуова ◽  
Г.А. Айтмуратова ◽  
Т.В. Полукчи ◽  
Ф.А. Бердалиева ◽  
Г.Г. Шаймерденова

Проведен литературный обзор об особенностях остаточных явлений и последствий COVID-19 на основе данных, опубликованных до настоящего времени. К началу января 2021 года COVID-19, сопровождающийся тяжелым острым респираторным синдромом, вызванным коронавирусом (SARS-CoV-2), привел к более чем 83 миллионам подтвержденных случаев и более чем 1,8 миллионам смертей. Клинический спектр инфекции SARS-CoV-2 широк, включая бессимптомную инфекцию, лихорадку, усталость, миалгии, легкое заболевание верхних дыхательных путей, тяжелую и опасную для жизни вирусную пневмонию, требующую госпитализации и летальный исход. COVID-19 - это новое заболевание, и остается неопределенность в отношении возможных долгосрочных последствий для здоровья. На сегодняшний день известно, что у большинства инфицированных, особенно в молодом возрасте, заболевание имеет легкое течение, по сравнению с лицами старшего возраста. У некоторых пациентов заболевание быстро прогрессирует и развиваются различные осложнения, в т.ч. полиорганная недостаточность. Поэтому раннее выявление и своевременное лечение критических случаев имеет решающее значение. A literature review on the features of residual phenomena and consequences of COVID-19 is analyzed on the basis of data published so far. By the beginning of January 2021, COVID-19, accompanied by severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2), led to more than 83 million confirmed cases and more than 1.8 million deaths. The clinical spectrum of SARS-CoV-2 infection is wide, including asymptomatic infection, fever, fatigue, myalgia, mild upper respiratory tract disease, severe and life-threatening viral pneumonia requiring hospitalization, and death. COVID-19 is a new disease, and uncertainty remains about possible long-term health consequences. To date, it is known that the majority of infected people, especially at a young age, have a mild course of the disease, compared with older people. In some patients, the disease progresses rapidly and various complications develop, including multiple organ failure. Therefore, early detection and timely treatment of critical cases is crucial.

2012 ◽  
pp. 536-557 ◽  
Author(s):  
Eric J. Parente ◽  
Samantha H. Franklin ◽  
Frederik J. Derksen ◽  
Michael A. Weishaupt ◽  
Heather J. Chalmers ◽  
...  

2019 ◽  
Vol 22 (6) ◽  
pp. 492-499
Author(s):  
Lucy Kopecny ◽  
David J Maggs ◽  
Christian M Leutenegger ◽  
Lynelle R Johnson

Objectives The aim of this study was to assess the effects of famciclovir administration in cats with spontaneously acquired acute upper respiratory tract disease. Methods Twenty-four kittens with clinical signs of acute upper respiratory tract disease were randomly allocated to receive doxycycline (5 mg/kg PO q12h) alone (group D; n = 12) or with famciclovir (90 mg/kg PO q12h; group DF; n = 12) for up to 3 weeks. Clinical disease severity was scored at study entry and daily thereafter. Oculo-oropharyngeal swabs collected at study entry and exit were assessed using quantitative PCR for nucleic acids of feline herpesvirus type 1 (FHV-1), feline calicivirus (FCV), Chlamydia felis, Bordetella bronchiseptica and Mycoplasma felis. Results The median (range) age of cats was 1.5 (1–6) months in group D vs 1.6 (1–5) months in group DF ( P = 0.54). Pathogens detected in oculo-oropharyngeal swabs at study entry included FCV (n = 13/24; 54%), M felis (n = 8/24; 33%), FHV-1 (n = 7/24; 29 %), C felis (n = 7/24; 29%) and B bronchiseptica (n = 3/24; 12%). Median (range) duration of clinical signs was 11.5 (3–21) days in group DF and 11 (3–21) days in group D ( P = 0.75). Median (range) total disease score at the end of the study did not differ between groups (group D 1 [1–1] vs group DF 1 [1–3]; P = 0.08). Conclusions and relevance This study revealed no significant difference in response to therapy between cats treated with doxycycline alone or with famciclovir; cats improved rapidly in both groups. However, identification of FHV-1 DNA was relatively uncommon in this study and clinical trials focused on FHV-1-infected cats are warranted to better evaluate famciclovir efficacy.


Sign in / Sign up

Export Citation Format

Share Document